FDA sent warning letters to five peptide sellers dated August 24, 2026. The Center for Drug Evaluation and Research (CDER) wrote to Peak Performance Peptides, Royal Peptides LLC, NuScience Peptides LLC, Peptide Partners LLC and TXP Innovations LLC (doing business as Tex Peptides) after reviewing their websites in July 2026 (MARCS-CMS 733652, 734884, 735063, 735067 and 735127). Each letter found research-labeled GLP-1 and other peptide products to be unapproved new drugs. FDA’s pages for the letters show content current as of September 1, 2026.
Quick answer: Did FDA say research peptides are illegal? Not in those words. FDA found that these five sellers’ websites showed their products were intended for human use, which made them unapproved new drugs despite research-only labels. The letters apply existing law. They do not create a new rule.
This article summarizes public regulatory records. It is not legal advice.
Who received the letters, and for which products?
Table 1 lists each recipient and the products FDA named as unapproved new drugs. Names are shortened to the compound; quoted names are as FDA wrote them. We do not repeat the sellers’ product claims.
FDA warning letters dated August 24, 2026
| Recipient (MARCS-CMS) | Products FDA named |
|---|---|
| Peak Performance Peptides, Phoenix, AZ (735127) | Semaglutide; “GLP-3R” (retatrutide); SS-31; PT-141; tesamorelin; “Bac water” |
| Royal Peptides LLC, Boynton Beach, FL (734884) | Tirzepatide; semaglutide; retatrutide; SS-31 (elamipretide); PT-141; tesamorelin; “BIMORELIN” |
| NuScience Peptides LLC, Cornelius, NC (733652) | Tirzepatide; semaglutide; retatrutide; survodutide; mazdutide; PT-141 (bremelanotide); tesamorelin; a tesamorelin and ipamorelin blend; bacteriostatic water |
| Peptide Partners LLC, Sarasota, FL (735063) | Semaglutide; tirzepatide; retatrutide; SS-31 (elamipretide); tesamorelin; PT-141 (bremelanotide); “Reconstitution Solution (BAC)” |
| TXP Innovations LLC dba Tex Peptides, Dallas, TX (735067) | Semaglutide; tirzepatide; retatrutide; SS-31 (elamipretide); tesamorelin; PT-141 (bremelanotide); bacteriostatic water |
Sources: the five FDA letters (FDA, 2026a; 2026b; 2026c; 2026d; 2026e).
What do the letters say?
The letters follow one structure. Each says the products are drugs under section 201(g)(1) because they are “intended for use in the diagnosis, cure, mitigation, treatment, or prevention of disease.” Each then finds them to be new drugs under section 201(p) that lack approval. The Royal Peptides letter, for example, states: “No approved applications pursuant to section 505 of the FD&C Act, 21 U.S.C. 355, are in effect for these products.”
The sellers’ labels used phrases such as “research use only,” “not for human consumption” and “not for human or veterinary use.” NuScience’s labeling said “for laboratory, research, and analytical use.” FDA looked past them. In the Royal Peptides, NuScience and Peptide Partners letters, it wrote that “evidence obtained from your website establishes that your products are intended to be drugs for human use.” All five letters cite 21 CFR 201.128, the rule on intended use.
That rule says intended use means the “objective intent” of the persons responsible for labeling. It may be shown by “labeling claims, advertising matter, or oral or written statements” (21 CFR 201.128).
Why did FDA mention bacteriostatic water?
The Peak Performance, NuScience, Peptide Partners and Tex Peptides letters each concluded that the seller’s bacteriostatic water was itself a drug, because it was sold to reconstitute peptide products intended for injection. The Royal Peptides letter said that its bacteriostatic water, together with a “peptide guide” and “peptide calculator,” provided the means to prepare an injectable drug for human administration.
What changes, and what does not?
No new law or rule came with these letters. They apply existing provisions of the Act to five companies. FDA’s page on unapproved GLP-1 drugs, current as of October 1, 2026, already said FDA has warned companies selling semaglutide, tirzepatide, retatrutide, survodutide or mazdutide products “falsely labeled” for research or not for human consumption (FDA, 2026f). Besides GLP-1 products, these letters also name SS-31, PT-141 and tesamorelin, and they treat bacteriostatic water as a drug when it is sold for reconstituting injectable products.
Who does it affect?
Online peptide sellers: the letters show FDA reading whole websites, not only labels. Compounders and prescribers: not addressed; these were not compounding letters. Researchers: the letters concern how products were marketed. Research-grade semaglutide, tirzepatide, retatrutide, SS-31 and tesamorelin in our catalog are sold for laboratory research use only, not for human or veterinary use, and are not substitutes for approved medicines.
What happens next?
Each letter asked for a written response within fifteen business days of receipt. The Peptide Partners letter, for example, asks for “the specific steps you have taken to correct any violations” and warns that failure to address them “may result in regulatory or legal action without further notice,” including seizure and injunction. It also says the letter is not an all-inclusive list of violations.
How does it fit the earlier history?
FDA has used the same approach for research-labeled products before. Our guide to FDA warning letters to peptide sellers collects the earlier rounds. For compound-level status, see is retatrutide legal, is semaglutide legal and is tirzepatide legal. Our page on what research use only means covers the labeling question.
Frequently asked questions about the August 2026 letters
How many peptide sellers did FDA warn on August 24, 2026?
Five: Peak Performance Peptides, Royal Peptides, NuScience Peptides, Peptide Partners and Tex Peptides.
Does a “research use only” label protect a seller?
Not by itself. FDA judged intended use from each seller’s website and found the products were intended for human use.
Why is bacteriostatic water in the letters?
FDA found that sellers offered it to reconstitute injectable peptide products, so four letters treated it as a drug.
What to know now
- Letters: five CDER warning letters dated August 24, 2026.
- Products: semaglutide, tirzepatide, retatrutide, SS-31, PT-141, tesamorelin and others.
- Law: unapproved new drugs under sections 505(a) and 301(d); intended use under 21 CFR 201.128.
- Labels: research-only wording did not change FDA’s conclusion.
What we’re watching
New FDA warning letters to peptide sellers, and any close-out letters or further action on these five firms.